Publication Name	World Journal of Diabetes
Manuscript ID	81161
Country	France

Received	2022-10-27 14:31
Peer-Review Started	2022-10-27 14:33
To Make the First Decision
Return for Revision	2022-12-26 08:30
Revised	2022-12-27 12:28
Second Decision	2023-02-10 03:37
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-02-10 18:18
Articles in Press	2023-02-10 18:18
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-03-09 10:36
Publish the Manuscript Online	2023-03-15 15:41

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Biology
Manuscript Type	Minireviews
Article Title	Carbamylated lipoproteins in diabetes
Manuscript Source	Invited Manuscript
All Author List	Damien Denimal
Funding Agency and Grant Number
Corresponding Author	Damien Denimal, PharmD, PhD, Assistant Professor, Department of Biochemistry, University Hospital of Dijon, 2 rue Ducoudray, BP 37013, Dijon 21079, France. damien.denimal@u-bourgogne.fr
Key Words	Carbamylation; Lipoprotein; Diabetes; Low-density lipoprotein; High-density lipoprotein; Myeloperoxidase
Core Tip	There is growing evidence that carbamylation of lipoproteins occurring in diabetes contributes to the pathophysiology of atherosclerosis, and therefore plays a role in the cardiovascular risk. Numerous studies have demonstrated that carbamylated low-density lipoproteins (LDL) is more atherogenic than native LDL, citing, for instance, its role in foam cell formation or ability to damage endothelial function. In addition, carbamylated high-density lipoproteins exhibits reduced antiatherogenic properties, especially in terms of the capacity to induce cholesterol efflux from macrophages and to protect endothelium.
Publish Date	2023-03-15 15:41
Citation	Denimal D. Carbamylated lipoproteins in diabetes. World J Diabetes 2023; 14(3): 159-169
URL	https://www.wjgnet.com/1948-9358/full/v14/i3/159.htm
DOI	https://dx.doi.org/10.4239/wjd.v14.i3.159

Full Article (PDF)	WJD-14-159.pdf
Full Article (Word)	WJD-14-159.docx
Manuscript File	81161_Auto_Edited-LM.docx
Answering Reviewers	81161-Answering reviewers.pdf
Audio Core Tip	81161-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	81161-Conflict-of-interest statement.pdf
Copyright License Agreement	81161-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	81161-Language certificate.pdf
Peer-review Report	81161-Peer-review(s).pdf
Scientific Misconduct Check	81161-Bing-Wang JJ-2.png
Scientific Editor Work List	81161-Scientific editor work list.pdf